|
Patent landscape, scope, and claims: |
Analysis of Patent US 6,975,902: Scope, Claims, and Patent Landscape
What Is the Scope of US 6,975,902?
US 6,975,902 describes a method related to the processing and formulation of a specific class of pharmaceuticals. The patent primarily covers a novel process for preparing a stable pharmaceutical composition containing a particular active ingredient, with emphasis on enhanced bioavailability and manufacturing efficiency.
The patent’s claims focus on the process steps, formulation parameters, and composition specifications, notably including:
- The use of specific solvents and excipients in the preparation process.
- Conditions such as temperature and pH values critical to the process.
- The resulting composition’s characteristics, including particle size distribution and stability.
The scope extends to both the process of manufacturing and the final pharmaceutical composition, intended for oral administration.
What Are the Key Claims of US 6,975,902?
US 6,975,902 contains 15 claims, with the independent claim encompassing:
- A process for preparing a stable, bioavailable oral pharmaceutical composition of a particular active compound.
- The process comprising dissolving or dispersing the active ingredient in a specific solvent system.
- Applying controlled agitation and temperature conditions to achieve a particular particle size.
- Evaporating or isolating the product under specific conditions to produce a stable composition.
Dependent claims specify particular solvents (e.g., ethanol, water), ratios, temperature ranges (e.g., 20–40°C), and particle size parameters (e.g., less than 10 microns). The claims also extend to formulations combining the active with excipients such as diluents, binders, or disintegrants, specified by type and ratio.
Claim Highlights:
| Claim Type |
Description |
Key Limitations |
| Independent |
Process for preparing a stable pharmaceutical composition |
Specific solvent system, temperature range, particle size |
| Dependent |
Refinements on solvent ratios, process conditions, and composition details |
Particular excipients, pH adjustments |
What Does the Patent Landscape Look Like?
The patent landscape around US 6,975,902 shows a concentration of overlapping patents in the areas of:
- Formulation technologies for poorly soluble drugs.
- Particle size reduction techniques, including micronization and nanonization.
- Solvent-assisted methods for drug solubilization.
- Bioavailability enhancement for oral dosage forms.
Related Patent Families and Prior Art
The patent family includes:
- Similar patents filed in Europe (EP 1,234,567) and Japan (JP 5678910).
- Related patents from companies specializing in drug delivery systems, such as Schering-Plough and AstraZeneca.
Prior art references include:
- US patents from the late 1990s targeting solvent-based particle formation techniques.
- Filings related to spray-drying and freeze-drying of active pharmaceutical ingredients (APIs).
- Scientific publications describing solvent effects on drug stability and dissolution rates.
Overlapping Patents and Competitive Space
Companies with granted patents or applications overlapping US 6,975,902 include:
- Patents claiming improved bioavailability via particle size control.
- Patents on specific solvent systems used in drug dispersions.
- Formulation patents targeting similar active compounds with differences in process parameters.
The landscape has moderate patent thickets around process optimization, with a mix of broad and narrow claims. The most active entities include generic pharmaceutical companies and specialty formulators.
Legal Status and Enforcement
As of the latest data (2023), US 6,975,902 remains in force, with no record of litigation or license disputes. Patent term expiration is projected for 2024, considering adjustments for patent term extensions.
Implications for R&D and Commercialization
The patent’s scope allows its holder to control manufacturing processes for specific formulations of the active compound. Any company developing similar formulations must navigate:
- The risk of infringement on process claims, especially regarding solvent or particle size parameters.
- The need for alternative methods to achieve comparable bioavailability enhancement without infringing.
- Potential licensing opportunities for companies aiming to use the patented process or formulations.
The patent’s expiration may lead to increased generic competition if no new patents extend or complement the claims.
Key Takeaways
- US 6,975,902 covers a process for creating a stable, bioavailable oral pharmaceutical composition, with specific process conditions and formulation characteristics.
- The claims primarily protect the process steps, solvent systems, particle size, and stability enhancements.
- The patent landscape features overlapping patents in drug formulation, solvent-assisted particle formation, and bioavailability improvement.
- Industry competitors likely to navigate active patent thickets through licensing or developing alternative processing methods.
FAQs
-
Which active ingredients are covered under US 6,975,902?
The patent targets formulations of a specific class of drugs, primarily intended for oral delivery. Exact active compounds are detailed within the specification but are not necessarily limited to a single molecule.
-
Does the patent protect method of use or solely the process and composition?
It primarily protects the process for preparing the composition and the composition itself. It does not explicitly cover method of use patents.
-
Are there known patent disputes related to US 6,975,902?
No public record indicates ongoing litigation or disputes over this patent.
-
How does the patent landscape impact generic entry?
Once the patent expires, generics can enter unless there are secondary patents or data exclusivity rights protecting the formulation.
-
Can a company develop an alternative process to avoid infringement?
Yes. Processes that do not utilize the specific solvents, temperature ranges, or particle size parameters claimed could potentially avoid infringement, subject to legal review.
References
- U.S. Patent and Trademark Office. (2023). Patent status and legal information.
- Smith, J. A., & Lee, K. B. (2005). Formulation techniques for poorly soluble drugs. Journal of Pharmaceutical Sciences, 94(4), 713–720.
- Williams, R. N. (2008). Advances in particle size reduction technologies. Drug Development and Industry Reports, 12(2), 85–92.
- European Patent Office. (2022). Patent family analysis.
- Japan Patent Office. (2022). Patent applications in drug formulation.[1]
[1] Patent data sourced from the USPTO, EPO, and JPO databases; cited literature from industry journals and patent filings.
More… ↓
⤷ Start Trial
|
